Codexis (NASDAQ: CDXS) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Codexis to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, profitability, institutional ownership and risk.

Earnings and Valuation

This table compares Codexis and its competitors revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Codexis $43.16 million -$15.16 million -14.27
Codexis Competitors $207.54 million -$2.40 million 0.00

Codexis’ competitors have higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Codexis has a beta of -1.37, meaning that its stock price is 237% less volatile than the S&P 500. Comparatively, Codexis’ competitors have a beta of 1.67, meaning that their average stock price is 67% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Codexis and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis 0 1 3 0 2.75
Codexis Competitors 788 2943 6421 144 2.58

Codexis currently has a consensus target price of $6.94, indicating a potential upside of 18.59%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.84%. Given Codexis’ stronger consensus rating and higher probable upside, research analysts plainly believe Codexis is more favorable than its competitors.


This table compares Codexis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Codexis -40.70% -83.39% -45.44%
Codexis Competitors -3,679.23% -415.77% -47.88%

Insider and Institutional Ownership

63.6% of Codexis shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 9.8% of Codexis shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Codexis beats its competitors on 7 of the 12 factors compared.

About Codexis

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive News & Stock Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related stocks with our FREE daily email newsletter.